Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China

被引：0
|
作者：
Luo, Xingxian [1 ]
Xu, Yang [2 ,3 ]
Du, Xin [4 ]
Lv, Xufeng [5 ]
Chen, Si [5 ]
Yang, Yue [2 ,3 ]
Huang, Lin [1 ]
Zhang, Xiaohong [1 ]
机构：
[1] Peking Univ, Dept Pharm, Peoples Hosp, Beijing, Peoples R China
[2] Tsinghua Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[3] Natl Med Prod Adm, Key Lab Innovat Drug Res & Evaluat, Beijing, Peoples R China
[4] Tsinghua Univ, Vanke Sch Publ Hlth, Beijing, Peoples R China
[5] Natl Med Prod Adm, Ctr Drug Evaluat, Beijing, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2024年 / 52卷
基金：
中国国家自然科学基金;
关键词：
SURVIVAL; ONCOLOGY;
D O I：
10.1016/j.lanwpc.2024.101238
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] PROGRESS IN THE SYSTEMIC TREATMENT OF CANCER - CONCEPTS, TRIALS, DRUGS, AND BIOLOGICS
    CARBONE, PP
    CANCER, 1990, 65 (03) : 625 - 633
  • [32] Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
    Wu, Yu
    Dong, Pu
    Wu, Qifang
    Zhang, Ya
    Xu, Gang
    Pan, Chenwei
    Tong, Haibin
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [33] Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers
    Zou, Limin
    Qi, Yueli
    Jiang, Yongling
    Tang, Ling
    Du, Yu
    Zhao, Boyuan
    Sun, Yanzhe
    Xiang, Meiyi
    Ma, Jun
    Yang, Zhimin
    CANCER COMMUNICATIONS, 2023, 43 (02) : 171 - 176
  • [34] Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
    McPhail, Melanie
    Weiss, Emma
    Bubela, Tania
    FRONTIERS IN MEDICINE, 2022, 8
  • [35] Early Phase Pediatric Cancer Trials: Progress Highlights Challenges
    Adamson, Peter C.
    ONCOLOGIST, 2020, 25 (06): : 468 - 469
  • [36] Analysis of Drugs for Hematological Malignancy That Were Granted Accelerated Approval and Feasibility of Randomized Phase 3 Clinical Trials for Relapsed and Refractory Hematological Malignancy
    Nagai, Sumimasa
    Ozawa, Keiya
    BLOOD, 2016, 128 (22)
  • [37] Participation of African Americans in clinical trials supporting FDA approval of cancer drugs.
    Al Hadidi, Samer
    Mims, Martha P.
    Miller-Chism, Courtney Nicole
    Kamble, Rammurti T.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Publisher Correction: Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
    Andrew J. Krentz
    Gerardo Rodriguez-Araujo
    Pharmaceutical Medicine, 2018, 32 (1) : 93 - 93
  • [39] Challenges in regulatory marketing approval of drugs for the treatment of advanced non-small cell lung cancer based on non-inferiority trials
    Sridhara, Rajeshwari
    Malik, Shakuntala
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S540 - S540
  • [40] Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours
    Desnoyers, Alexandra
    Wilson, Brooke E.
    Nadler, Michelle B.
    Amir, Eitan
    CANCER TREATMENT REVIEWS, 2021, 94
12345